Tirzepatide 10mg is one of 2 Tirzepatide vial sizes NuVion stocks in Australia. This size is $89.00, or $8.90 per mg. See all Tirzepatide sizes.
Tirzepatide, sometimes shortened to tirz, is a synthetic 39 amino acid peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It is used as a reference compound in incretin and receptor signalling research in vitro, and NuVion stocks it in Australia in 10mg and 60mg vials.
- Dual agonist at the GIP and GLP-1 receptors
- Used in pancreatic beta cell, hepatocyte and adipocyte models
- Applied in receptor binding and second messenger assays
- Supplied lyophilised, purity by RP-HPLC and identity by mass spectrometry
Tirzepatide receptor profile
Tirzepatide is a single-chain peptide carrying a C20 fatty diacid side chain. It binds and activates two class B G protein-coupled receptors, GIP and GLP-1, which both signal through Gs and cyclic AMP. That places it between single GLP-1 receptor agonists and triple agonists such as retatrutide, and makes it the reference dual agonist in receptor selectivity and cAMP accumulation work.
Tirzepatide vial sizes and prices, 10mg and 60mg
NuVion stocks tirzepatide in 10mg and 60mg vials. Both hold the same lyophilised peptide, and the 60mg vial works out cheaper per milligram.
| Vial size | Price | Price per mg | Availability |
|---|---|---|---|
| Tirzepatide 10mg | A$89.00 | A$8.90/mg | In stock |
| Tirzepatide 60mg | A$249.00 | A$4.15/mg | In stock |
Tirzepatide research applications
- HTRF or GloSensor cAMP assays in cell lines expressing GIPR or GLP-1R separately
- Competition binding against labelled GIP and GLP-1 analogues on membrane preparations from receptor-expressing cells
- Paired cAMP and beta-arrestin concentration-response curves to quantify signalling bias at GLP-1R
- Cryo-EM and hydrogen-deuterium exchange mass spectrometry on peptide, receptor and G protein complexes
Tirzepatide key facts
| Type | Synthetic lipidated peptide, dual GIPR and GLP-1R agonist |
|---|---|
| Amino acid count | 39 residues, C-terminal amide |
| Modifications | Aib at positions 2 and 13; Lys20 conjugated to a C20 fatty diacid through a gamma-glutamate and two AEEA spacers |
| Also known as | LY3298176, dual GIP and GLP-1 receptor agonist |
| Purity | 99.74% by RP-HPLC, Janoshik Analytical |
| Analysed | 24 September 2026 |
Research profile: Tirzepatide: structure, mechanism and research use
Independent test: a sample of this product was analysed by Janoshik Analytical on 24 September 2026, purity 99.74% by RP-HPLC, test number 234338. The full report opens from the lab band on this page.







